letterEmerging Microbes & InfectionsJan 1, 2020GOLD OA

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

JMJuan MengGXGuohui XiaoJZJuanjuan ZhangXHXing HeMOMin Ou

Southern University of Science and Technology · Shenzhen Bay Laboratory · +2 more institutions

PubMed
Indexed incrossrefdatacitedoajpubmed

Abstract

The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other…

Citation impact

649
total citations
FWCI
15.73
Percentile
100%
References
14
Citations per year

Authors

13

Topics & keywords

Topics
Keywords
  • Medicine
  • Renin–angiotensin system
  • Coronavirus disease 2019 (COVID-19)
  • Angiotensin Receptor Blockers
  • Internal medicine
  • Peripheral
  • Disease
  • CD8
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding